Total Pageviews

Monday, October 25, 2010

FW: Derivatives Info Kit

 

 

From: Sharekhan Derivatives Research [mailto:newsletter@mailer.sharekhan.com]
Sent: Monday, October 25, 2010 6:46 PM
To: rnbhatsirsi@gmail.com
Subject: Derivatives Info Kit

 

 

Derivatives Info Kit

[For October 26, 2010]

Sharekhan
www.sharekhan.com

 Summary of Contents

 

DERIVATIVES INFO KIT

 


Click here to read report: Derivatives Info Kit

 

 

 

Regards,
The Sharekhan Research Team

myaccount@sharekhan.com

Manage your newsletter subscriptions

 

FW: Investor's Eye: Update - HUL (PT under review), Piramal Health (PT revised to Rs522), BoI (PT revised to Rs533)

 

 

From: Sharekhan Fundamental Research [mailto:newsletter@mailer.sharekhan.com]
Sent: Monday, October 25, 2010 8:35 PM
To: rnbhatsirsi@gmail.com
Subject: Investor's Eye: Update - HUL (PT under review), Piramal Health (PT revised to Rs522), BoI (PT revised to Rs533)

 

 

Investor's Eye
October 25, 2010] 

Sharekhan
www.sharekhan.com

Summary of Contents

STOCK UPDATE

Hindustan Unilever
Cluster: Apple Green
Recommendation: Reduce
Price target: Under review
Current market price: Rs306

Price target under review

Q2FY2011 results: First-cut analysis 

  • Hindustan Unilever Ltd (HUL)?s Q2FY2011 results are in line with our expectations. The adjusted net profit stood flat at Rs534.2 crore (in line with our estimate of Rs526.7 crore), mainly on account of a higher than expected other income during the quarter. 
  • The company?s net sales grew by 10.7% year on year (YoY) to Rs4,680.9 crore driven by a strong year-on-year (Y-o-Y) growth of 14% in the sales volume of the domestic consumer business (higher than the Y-o-Y growth of 10.9% and 10.3% in Q4FY2010 and Q1FY2011 respectively). 
    • The household & personal care (HPC) business grew by 9% YoY with a good growth across the product portfolio. As anticipated, the soap and detergent segment grew by 6.3% YoY with a strong volume growth in the laundry segment. The personal care segment registered a growth of 15% YoY on the back of a double-digit volume growth. 
    • The food business grew by 13% YoY as the beverage segment grew by 9% YoY and the process foods segment, continuing its strong performance, grew by 26.2% YoY during the quarter.
  • Despite a benign raw material cost (as a percentage of the total sales) on a Y-o-Y basis the operating profit margin (OPM) declined by 242 basis points YoY to 12.0% (below our expectation of 13.1%), mainly on account of a 232-basis-point Y-o-Y surge in the operating expenses as a percentage of the total sales. Thus, the operating profit declined by 7.8% YoY to Rs563.1 crore during the quarter (below our expectation of Rs607.4 crore).
  • The advertisement cost as a percentage of the total sales stood flat at 13.8% in Q2FY2011 (the same was down by 186 basis points on a quarter-on-quarter basis).
  • The higher than expected other income caused the adjusted net profit to remain flat at Rs534.2 crore during the quarter (in line with our expectation of Rs526.7 crore). The other income during the quarter stood at Rs160.6 crore as against Rs88.4 crore in Q2FY2010 (the same was also higher than our expectation of Rs120.0 crore). 
  • After including the exceptional item of Rs32 crore (post-tax), the reported net profit grew by 32.1% YoY to Rs566.1 crore during the quarter.
  • Under the ongoing buy-back scheme the company (till September 2010) has bought back 2 lakh shares at an average price of Rs266.75 for a total consideration of Rs5.34 crore. Considering the approved maximum outlay of Rs630 crore for the buy-back, the company could further buy back 2.23 crore equity shares at a cap price of Rs280 per share.
  • The sustenance of the strong volume growth in the coming quarters would help HUL to achieve a double-digit topline growth in FY2011. However, rising input cost and advertisement & promotional spends are the key headwinds that HUL will face on the margin front in the coming quarters. We will review our estimates and come out with a detailed result note after the conference call with the management of the company tomorrow. At the current market price the HUL stock trades at 30.0x its FY2011E earnings per share (EPS) of Rs10.2 and 25.1x its FY2012E EPS of Rs12.2. Currently, we have a Reduce rating on the stock.

 

Piramal Healthcare
Cluster: Apple Green
Recommendation: Hold
Price target: Rs522
Current market price: Rs495

Price target revised to Rs522

Result highlights

  • Buyback unattractive at Rs600 per share: Piramal has chosen to buy back up to 20% of its equity at Rs600 per share. Promoters would also participate in the buyback, tendering their equity in the same proportion as the minority share holders. The buyback would entail a cash outflow of Rs2,508 crore and is likely to be completed by February 2011. We believe that the buyback holds little to no interest for the investors like the issue of the dividend and could put the stock under some pressure. The stock could stabilise approximately at a level of Rs468. The investors can look at buying opportunities at dips.
  • Results below estimates: Piramal Healthcare (Piramal)?s revenues de-grew by 25% year on year (YoY) to Rs752 crore, which is below our estimates of Rs849 crore as the management concentrated on the closure of the Abbott transaction. Piramal reported an operating loss of Rs25.4 crore for the quarter which factors in the impact of the one-time expense of Rs120 crore as bonus payment to employees from the deal closure and a foreign exchange (forex) loss of Rs12.65 crore. Operating margins stood at negative 3.4%. The net profit for the quarter stood at Rs12,540 crore after factoring in a) a net exceptional income of Rs16,224 crore from the sale of the healthcare business to Abbott and b) a tax outgo amounting to Rs3,600 crore for the quarter. After adjusting for exceptional gains, the net loss at profit before tax (PBT) level stood at Rs40 crore.
  • Base business disappoints: The uncertainty in the healthcare solutions business (down by 21.9% as against an industry growth of 15-16%) as well as the transition costs associated with the sale of the business resulted in a negative top line growth of 26.3% during the quarter. The contract research and manufacturing services (CRAMS) segment posted a decline of 27.6% YoY with Indian assets declining by 40.6%. The critical care business also disappointed and declined by 27.7% YoY (the lowest in the past six quarters). 
  • Revise estimates downwards: The management guided for a downward revision in the company?s numbers in Q3FY2011 as it would fail to meet certain targets. Given the disappointing performance in the residual businesses, we have reduced our earnings estimates for the residual businesses. Our revised earning per share (EPS) stands at Rs9.2 for FY2011E and Rs15.7 for FY2012E on an adjusted basis.
  • Maintain Hold, price target of Rs522: We remain cautious on the stock due to the risk associated with the utilisation of cash proceeds from the Abbott and Religare deals. More clarity should set in from Q3FY2011 onwards. Therefore, while the net present value (NPV) of these cash proceeds is Rs528, we ascribe a 20% discount to this value; our risk adjusted NPV thus stands at Rs422. We value the residual business at Rs99, bringing our total price target to Rs522, a 5.5% upside from the current levels.

 

Bank of India
Cluster: Apple Green
Recommendation: Hold
Price target: Rs533
Current market price: Rs520

Price target revised to Rs533

Result highlights

  • Results below expectations: For Q2FY2011 Bank of India (BoI) reported a net profit growth of 90.7% year on year (YoY) to Rs617 crore. The profit growth was aided by the low base of the previous year. On a sequential basis, however, the performance was muted with the bank recording a 15% contraction in its bottom line. The bank?s net profit for the quarter stood below our expectations as well as the street?s expectations due to higher than expected provisioning during the quarter. 
  • Strong NII growth: The net interest income (NII) was up a strong 26.1% YoY to Rs1,776.1 crore, supported by a healthy 22.6% year-on-year (Y-o-Y) growth in the advances as well as a 24-basis-point Y-o-Y improvement in the reported net interest margin (NIM) to 2.81%. On a sequential basis, however, the reported NIM deteriorated by eight basis points due to a 30-basis-point sequential increase in the cost of funds. 
  • Provisions rise 36.7% sequentially: The provisions stood at Rs527.4 crore, up 36.7% sequentially; the same stood above our expectations as the bank made certain floating provisions in order to reach the provision coverage mandate of 70% (including technical write-offs). 
  • Slippages pose significant concern: The asset quality of the bank improved sequentially with the rise in its gross non-performing assets (GNPAs) contained at 1.6% quarter on quarter (QoQ) on the back of higher write-offs. On a relative basis, the bank saw a seven-basis-point improvement in its %GNPA to 2.64%. The percentage of its net non-performing assets (NNPAs) also witnessed an improvement of four basis points sequentially to 1.14%. Despite the reduction in the %GNPAs, the underlying asset quality remained weak as slippages remained high. The slippages for the quarter stood at Rs818.4 crore as compared to Rs618 crore for the previous quarter.
  • Maintain Hold with a revised price target of Rs533: BoI?s Q2FY2011 performance was disappointing in terms of asset quality. Hence, we have revised our estimates for the company to factor in the acceleration in provisioning as well as the sustained high level of slippages. At the current market price of Rs520, BoI trades at 8.1x FY2012E earnings per share (EPS), 4.2x FY2012E pre-provisioning profit (PPP) per share and 1.8x FY2012E adjusted book value (ABV) per share. We maintain our Hold recommendation on the stock with a revised price target of Rs533.

 

Click here to read report: Investor's Eye

 

 

Regards,
The Sharekhan Research Team

myaccount@sharekhan.com 

Manage your newsletter subscriptions

 

Friday, October 22, 2010

FW: Derivatives Info Kit

 

 

From: Sharekhan Derivatives Research [mailto:newsletter@mailer.sharekhan.com]
Sent: Friday, October 22, 2010 8:32 PM
To: rnbhatsirsi@gmail.com
Subject: Derivatives Info Kit

 

 

Derivatives Info Kit

[For October 25, 2010]

Sharekhan
www.sharekhan.com

 Summary of Contents

 

DERIVATIVES INFO KIT

 


Click here to read report: Derivatives Info Kit

 

 

 

Regards,
The Sharekhan Research Team

myaccount@sharekhan.com

Manage your newsletter subscriptions

 

FW: Weekly-market: Markets shut week with modest gains

 

 

From: Sharekhan Market Commentary [mailto:newsletter@mailer.sharekhan.com]
Sent: Friday, October 22, 2010 10:28 PM
To: rnbhatsirsi@gmail.com
Subject: Weekly-market: Markets shut week with modest gains

 

 Sharekhan's weekly newsletter

Visit us at www.sharekhan.com

Error! Filename not specified. 

October 22, 2010

 

 Market Commentary 

Markets shut week with modest gains

The domestic markets snap two-week losing streak and end flat with a positive bias


Major news for the week:

  • Food inflation eases to 15.53%
  • Larsen & Toubro Q2 net profit jumps 31% yoy
  • Tata Consultancy Services hits all-time high on strong Q2 results
  • Cairn-Vedanta deal seeks our approval: ONGC
  • India's April-September direct tax receipts up 19%

Indian markets ended the week marginally higher breaking a two-week losing streak. The markets remained volatile throughout the week. The biggest buzz of the week was the India's largest initial public offering of Coal India as it attracted huge attention of foreign institutional investors (FIIs). During the week, China surprised the investors by raising its lending and deposit rates, prompting concern that the global economic recovery may slow. At back home, easing of inflation provided much needed support to the domestic markets. India's food inflation eased to 15.53% for the week ended October 09, 2010 as against 16.37% seen in the previous week.

Two of the India?s leading software developers posted contrasting Q2 results as Tata Consultancy Services posted robust results during the week, while Wipro declared its Q2 results below Street?s expectation.

During the week, the Sensex and the Nifty had hit one-month low and swung 529 and 160 points respectively. Wrapping the week, the Sensex shut marginally higher by 41 points or 0.20%, at 20166 and the Nifty closed higher by mere three points or 0.06% at 6066.

On the global front, the European markets outperformed the other world markets, as FTSE 100, Dax 100 and CAC40 surged over 1% each. While Hang Seng index lost the most by 1.01% in this week. The Sensex and China?s Shanghai Composite ended the week flat.

Among the 13 sector indices, eight ended the week in the green while five in the red. BSE Health Care (HC) was the top performer, up by 2.85% followed by BSE Oil & Gas that surged by 2.69% and BSE Capital Goods (CG) rose by 1.09%. BSE Metal was the major loser, down by 2.69%, followed by BSE Realty that declined by 2.18% and BSE Consumer Durables (CD) fell by 0.87%. 

In 'A' group stocks, Pipavav Shipyard was the star stock of the week, up by 20.86%, followed by Central Bank of India that was up by 15.82% and Indiabulls Financial Services advanced by 14.80%. In the losers' list, Sesa Goa was the top loser, down by 8% after posting weak Q2 results, followed by Mahindra & Mahindra Financial Services that fell by 7.69% and Apollo Tyres slipped by 6.62%. 

The FIIs continued there buying activity in this week. FIIs bought Indian shares worth a net of Rs3,598.20 crore as compared to net buy of Rs8,613.60 crore seen in the previous week, almost half of what was seen in the last week. The local investors sold the Indian stocks worth a net of Rs859.20 crore as against net sell of Rs1,348.50 crore seen in the previous week.

In the upcoming week, quarterly results will continue to flow and set the tone for the domestic markets in the near-term. 

 TOP MOVERS (GROUP A) 

Company

Price (Rs)

% chg

Gainers

Pipavav Shipyard

92.70

20.86

Central Bank

228.10

15.82

Indiabulls Financial Ser

210.95

14.80

Losers

Sesa Goa

342.90

-8.00

M&M Financial

654.40

-7.69

Apollo Tyres

76.20

-6.62

 

 FII/MF ACTIVITIES

Rs (cr)

FII

MF*

Gross purchase

17,150

1,539

Gross sale

13,552

2,398

Net investment

3,598

-859

*As on October 20, 2010

The stock specific action will be seen in Dr Reddy?s Laboratories, Hindustan Unilever, Sterlite Industries, NTPC, Oil & Natural Gas Corporation, Steel Authority of India, Cairn India, Punjab National Bank, ITC, ICICI Bank, Mahindra & Mahindra, Bharat Heavy Electricals, Maruti Suzuki and Suzlon Energy, as the companies will declare their Q2 results in the next week. The developments across the globe and foreign fund flows will also play a significant role in deciding the future path of the markets.

To know more about our products and services, click here.

?This document has been prepared by Sharekhan Ltd. This Document is subject to changes without prior notice and is intended only for the person or entity to which it is addressed to and may contain confidential and/or privileged material and is not for any type of circulation. Any review, retransmission, or any other use is prohibited. Kindly note that this document does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction.
Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. SHAREKHAN will not treat recipients as customers by virtue of their receiving this report.
The information contained herein is from publicly available data or other sources believed to be reliable. While we would endeavour to update the information herein on reasonable basis, SHAREKHAN, its subsidiaries and associated companies, their directors and employees (?SHAREKHAN and affiliates?) are under no obligation to update or keep the information current. Also, there may be regulatory, compliance, or other reasons that may prevent SHAREKHAN and affiliates from doing so. We do not represent that information contained herein is accurate or complete and it should not be relied upon as such. This document is prepared for assistance only and is not intended to be and must not alone betaken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. We do not undertake to advise you as to any change of our views. Affiliates of Sharekhan may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. 
This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SHAREKHAN and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.
SHAREKHAN & affiliates may have used the information set forth herein before publication and may have positions in, may from time to time purchase or sell or may be materially interested in any of the securities mentioned or related securities. SHAREKHAN may from time to time solicit from, or perform investment banking, or other services for, any company mentioned herein. Without limiting any of the foregoing, in no event shall SHAREKHAN, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. Any comments or statements made herein are those of the analyst and do not necessarily reflect those of SHAREKHAN.?

To unsubscribe write to myaccount@sharekhan.com

 

Manage your newsletter subscriptions

 

FW: Investor's Eye: Update - BoI (First-cut analysis), Wipro (Results below expectations), Ipca Lab (PT revised to Rs346), TCS (PT revised to Rs1,161), Allahabad Bank (Upgraded to Buy)

 

 

From: Sharekhan Fundamental Research [mailto:newsletter@mailer.sharekhan.com]
Sent: Saturday, October 23, 2010 2:09 AM
To: rnbhatsirsi@gmail.com
Subject: Investor's Eye: Update - BoI (First-cut analysis), Wipro (Results below expectations), Ipca Lab (PT revised to Rs346), TCS (PT revised to Rs1,161), Allahabad Bank (Upgraded to Buy)

 

 

Investor's Eye
October 22, 2010] 

Sharekhan
www.sharekhan.com

Summary of Contents

STOCK UPDATE

Bank of India
Cluster: Apple Green
Recommendation: Hold
Price target: Under review
Current market price: Rs536

Q2FY2011 results: First-cut analysis

Result highlights

  • Results below expectations: Bank of India reported a net profit growth of 90.7% year on year (YoY) to Rs617 crore, aided by the low base of the previous year. On a sequential basis however, the performance was muted with the bank recording a 15% contraction in its bottom line. Net profit for the quarter stood below our as well as Street expectations due to higher than expected provisioning. 
  • Strong NII growth: The net interest income (NII) was up a strong 26.1% YoY to Rs1,776.1 crore, supported by a healthy 22.6% Y-o-Y growth in the advances as well as a 24 basis points YoY improvement in the reported net interest margin (NIM) to 2.81%. On a sequential basis however, the reported NIM deteriorated by 8 basis points due to the 30 basis points sequential increase in the cost of funds. 
  • Lower treasury income restricts non-interest income growth: The non-interest income dropped 13.5% YoY as a result of a 76.2% Y-o-Y contraction in the treasury income. However core fee income growth remained strong, registering a rise of 21.4% YoY.
  • Provisions rise 36.7% sequentially: The provisions stood at Rs527.4 crore, up 36.7% sequentially. The same stood above our expectations as the bank made certain floating provisions in order to reach the provision coverage mandate of 70% (including technical write offs). 
  • Asset quality improves sequentially: The asset quality of the bank improved sequentially with the rise in gross non performing assets (GNPAs) contained at 1.6% quarter on quarter (QoQ). On a relative basis, the bank saw a 7 basis points improvement in its %GNPAs to 2.64%, percentage net non performing assets (%NNPAs) also witnessed an improvement of 4 basis points sequentially to 1.14%. 
  • Slippages pose significant concern: Despite the improvement in the asset quality, the continued high level of slippages poses some concern. Slippages for the quarter stood at Rs818.4 crore as compared to Rs618 crore for the previous quarter. Slippages stood higher sequentially, despite the bank having booked around Rs200 crore worth of GNPAs arising under the agri debt waiver in the previous quarter. 
  • High slippages in restructured accounts: The bank restructured assets of around Rs346 crore during the quarter, taking the total restructured assets portfolio to around 5.5% of total advances. Of these around 20% have slipped into non performing asset (NPA) category. 
  • Healthy business growth: The business growth of the bank was healthy with advances growing by 22.6% YoY. Meanwhile, the deposits too registered a healthy growth of 21.3% YoY with the current account and savings account (CASA) deposits as a percentage of domestic deposits expanding by 217 basis points YoY to 33.2%.
  • Adequately capitalised: The capital adequacy ratio (CAR; as per Basel II norms) as on September 30, 2010 stood at 13.04% with tier-I CAR at 8.38%. 
  • At the current market price of Rs536, the stock trades at 8.2x FY2012E earnings per share (EPS), 4.5x FY2012E pre-provisioning profit (PPP) per share and 1.5x FY2012E adjusted book value (ABV) per share. We will revert with a detailed analysis of the bank?s Q2FY2011 performance shortly. 

 

Wipro
Cluster: Apple Green
Recommendation: Buy
Price target: Rs528
Current market price: Rs450

Results below expectations

Result highlights

  • Performance below expectation: Wipro?s performance for Q2FY2011 has come below our expectations on the information technology (IT) services revenues and the margins front. For the quarter under review, IT services revenues were higher by 5.7% quarter on quarter (QoQ) to $1,272.8 million, but lower than our expectation of $1,287.4 million. On a sequential basis, volumes grew by 6.6% and realisation by 0.9% QoQ due to higher offshore share of revenues (up 50 basis points at 48.3%). On the other hand, IT services? earnings before interest and tax (EBIT) margins declined by 240 basis points QoQ to 22.2%, which is below our expectation of 23.6%. In rupee terms, the consolidated revenues were higher by 8.1% QoQ to Rs7,771.9 crore, which are marginally higher than our expectation of Rs7,654.2 crore, largely on the back of better than expected revenues in the product business, which was higher 28.5% QoQ to Rs1,069.3 crore. For Q3FY2011, Wipro has guided for an impressive 3.5%-5.5% sequential growth in revenues in US dollar terms to $1,317-$1,343 million. 
  • For the quarter under review, Wipro?s reported net profit at Rs1,284.9 crore, declined by 2.5% QoQ, lower than our expectation of Rs1,361.9 crore. Lower than expected net profit performance was largely on account of a decline in the IT services margins coupled with higher than expected loss in foreign exchange (forex) to the tune of Rs41.4 crore against a forex gain of Rs45.8 crore in the sequential quarter.
  • Decent volume growth, however lower than expectations: For Q2FY2011, IT services in US dollar terms were higher by 5.7% in reported currency terms to $1,272.8 million, which is below our expectation. On a constant currency basis, revenues were higher by 4.8% QoQ to $1,261 million. Revenue growth in the IT services was largely aided by sequential blended volume growth of 6.6%, which was below our expectation of 7.6% sequential volume growth. On the other hand, realisation remained stable during the quarter, with onsite realisation up by 1.1% and offshore by 0.1%. On a blended basis realisation was down 0.9% QoQ due to higher offshore contribution. 
  • Margins performance disappoints: IT services? EBIT margins for the quarter were down 240 basis points QoQ to 22.2%, which is below our expectation of 23.6%. Margins were largely impacted by people related costs ie restricted stock units charge and promotions. For the quarter Wipro gave promotion to about 19,000 employees. 
  • Impressive growth across verticals: During the quarter, Wipro saw broadbased sequential growth across the industry verticals led by retail and transportation (10%), healthcare (9.5%), telecom (7%), energy and utilities (6.9%), financial services (5.7%), manufacturing (3.6%) and technology (2%). Revenues from communication and media providers were flat. In terms of service offerings, the sequential growth was led by product engineering (17%), package implementation (6.5%), technology infrastructure services (6.2%), testing services (5.7%), application development and maintenance (4.7%) and business process outsourcing (2.6%). In term of geographies, APAC and other emerging markets led with a 12% sequential growth. Europe grew by 10.3% and the largest contributor Americas grew by 3.2%. 
  • Management commentary remains optimistic: Wipro?s management indicated at a strong demand environment going forward with discretionary spending also kicking in. Also, the funnel is increasing at a steady rate quarter over quarter. During the quarter, Wipro won seven large deals on the back of a similar number of wins in the previous quarter. The growth would be led by US with demand across healthcare, retail, banking and energy and utilities segments. However, there is some slackness in the technology and telecom verticals. The company is seeing traction in system integration deals from India and the Middle East. The management expects pricing to increase next year. 
  • Upward tweak in estimates: For the quarter gone by, Wipro?s performance was below our expectation on the IT services volume front and the margin front. In the last one year, Wipro has languished on the volume growth front as compared to its peers as the company?s key industry verticals like technology, manufacturing and telecom are still not entirely out of the woods and are still lagging behind the strong growth witnessed in the financial services sector where Wipro has lower contribution to revenues (27%), as compared to its peers. As the demand environment becomes broader going forward, we expect Wipro to catch up on the volume front in the coming quarters. We have marginally revised our earnings estimates for FY2011E and FY2012E. However we have increased our one year target multiple to 21x from 20x earlier on a rolling price earning (PE) basis. We maintain our 12 month target price of Rs528. At the current market price of Rs450, the stock trades at 20x FY2011 and 18x FY2012 estimated earnings. We maintain our Buy recommendation on Wipro. 

 

Ipca Laboratories
Cluster: Ugly Duckling
Recommendation: Buy
Price target: Rs346
Current market price: Rs298

Price target revised to Rs346

Result highlights

  • Revenues in line, PAT below estimates: For Q2FY2011 Ipca Laboratories (Ipca) reported an adjusted net profit of Rs65.2 crore. The adjusted net profit grew by a mere 1.1% year on year (YoY) and was below our expectation of Rs75.1 crore, largely due to a higher than expected tax rate during the quarter. The total income of the company grew by 20.5% to Rs518.3 crore, which was in line with our estimate of Rs514.3 crore, essentially due to a 29.4% Y-o-Y growth in the formulations business. The operating profit margin (OPM) contracted by 100 basis points to 22.8% on account of higher marketing and freight costs (up 170 basis points).
  • Anti-malarial sales led the growth: The 29.4% Y-o-Y growth in the domestic formulation business and a pick-up in the export of formulations (up 27.1% YoY; institution tender ?up 208%; generic?up 38%) elevated the sales. This was largely contributed by a 41% YoY growth in the anti-malarial formulation sales. The emerging markets showed good traction in H1FY2011?the Latin American market grew by 117%, Asia (up by 54%), Africa (up by 18%)?and the US market grew by 73%. The company remains confident on Russia/CIS sales in H2FY2011 and a 25% growth in international branded formulations for FY2011.
  • USFDA approval for Indore SEZ to act as a trigger: The USFDA is expected to inspect the plant in February-March 2011 while the UK MHRA has completed the inspection in this quarter. Ipca would start supplies to Europe from December 2010. However the new revenue channels would start once the USFDA approval is received. Ipca has increased its capital expenditure (capex) guidance to Rs220 crore from Rs150 crore earlier in FY2011. Of this, Rs90 crore will be utilised towards the Sikkim facility while the rest would be utilised for building two new API plants in Ratlam.
  • Raise estimates, maintain Buy: The Q2FY2011 results are below our estimates owing to higher than expected tax rate. However the revenues were in line with our estimates owing to strong contribution from both the domestic and export formulations largely aided by the robust recovery in the anti-malarial sales. We tweak our estimates to factor in the strong growth in the domestic formulations business and the higher tax guidance by the company. Our revised earning per share (EPS) estimates stand at Rs20 for FY2011 (vs Rs18.1 earlier) and at Rs23.8 for FY2012 (vs Rs22.6 earlier). At the current market price of Rs298, Ipca is attractively valued at 14.9x FY2011E earnings and 12.5x FY2012E earnings. Based on the strong earnings visibility from the export segment and the scale-up in the US business, we maintain our Buy recommendation on the stock with a revised price target of Rs346. 

 

Tata Consultancy Services
Cluster: Evergreen
Recommendation: Hold 
Price target: Rs1,161
Current market price: Rs1,046

Price target revised to Rs1,161

Result highlights

  • Q2 results beat the most optimistic expectations of the Street: Tata Consultancy Services (TCS) has continued to surprise the market with its strong numbers for the past few quarters. In Q2FY2011, TCS surpassed the most optimistic expectations of the market on all fronts, with an 11.7% revenue growth in US Dollar terms to $2,004 million. The growth was aided by a phenomenal volume expansion of 11.2% quarter on quarter (QoQ). In rupee terms, TCS? revenues increased by 13% QoQ to Rs9,286.4 crore, aided by better rupee realisation during the quarter. For the quarter under review, TCS has reported a foreign exchange (forex) loss of Rs53.7 crore; as a result of this loss its net other income declined by 72% QoQ to Rs33.7 crore during the quarter. The net profit for the quarter was higher by 14.2% QoQ to Rs2,106.5 crore, around 6.7% higher than our expectations. 
  • Strong volume momentum continues: In Q2FY2011, TCS? consolidated revenues in US Dollar terms grew by 11.7% on reported currency basis to $2,004 million, which was 4.8% ahead of our expectations. On a constant currency basis, the revenues were higher by 11% QoQ. The volume grew by 11.2% sequentially whereas the pricing declined by 26 basis points QoQ. TCS continues to show a strong volume growth. As a matter of fact, in the previous six quarters, TCS had reported an average sequential volume growth of 6.3%. The TCS management has indicated that the growth traction across geographies and industry verticals will be strong going forward. The net addition of more than 10,000 headcounts during the second quarter clearly indicates the visibility of its volume growth for the coming quarters is strong.
  • Impressive margin performance continues: The company?s earnings before interest, tax depreciation and amortisation (EBITDA) margin for the quarter under review expanded by 70 basis ponts to 30%, which was ahead of our expectations of a 10-basis-point decline QoQ. Despite facing headwinds on account of people related cost (promotions and higher variable pays), which affected its margin by 166 basis points, TCS managed to expand its margin sequentially driven by productivity improvement and selling, general and administrative (SG&A) leverage coupled with currency tailwinds that added 103 basis points to the margin. Going forward, we have factored in a stable margin performance in our estimates with an expansion of 70 basis points in FY2011 and a marginal contraction of 20 basis points in FY2012. We expect a better top line growth and productivity improvement to compensate for the currency headwinds. 
  • All-round growth across verticals: During the quarter under review, all the major industry verticals showed a strong growth momentum: Banking, financial services & insurance (BFSI; 10%), telecommunications (telecom; 12.6%), manufacturing (11.7%), retail and distribution (10.7%), transportation (15.3%), energies and utilities (45.6%), and life science and healthcare (9.6%). Among the geographies, the USA crossed $1 billion revenues in the quarter for the first time, growing by 9% sequentially. The Indian revenues grew by 25.7%, the Asia-Pacific revenues increased by 17.4%, the revenues from continental Europe grew by 14.2% and the revenues from the UK increased by 13.2%. The growth was across service lines with revenues from the infrastructure management services segment growing by 20.7%, the enterprise solution revenues up 17.4%, the engineering & industrial solutions revenues up 14%, the assurance services revenues up 15.2%, the business intelligence revenues up 15.8% and the business process outsourcing services revenues up 8.7%. The revenues from application development and maintenance grew by 9.1%, contributing 46.8% of the overall revenues. 
  • Valuation and view: The management commentary on the outlook for TCS? business is quite positive and hints at a strong deal pipeline and robust demand environment going ahead. On the other hand, the management has also indicated that the discretionary spending and pricing may pick up by the latter part of the fiscal. We have revised upward our earnings per share (EPS) estimates for FY2011 and FY2012 by 9.4% and 10.2% respectively. We have now valued both TCS and Infosys Technologies (Infosys) on 23x FY2012E as against our earlier investment thesis of valuing TCS at a 10% discount to Infosys? target price/earnings (P/E) multiple, as we believe TCS will continue to outperform Infosys in the medium term. Consequently, we have revised upward our 12-month price target to Rs1,161 from Rs920 earlier. At our price target the stock would be valued at 23x FY2012E. We maintain our Hold recommendation on the stock. 

 

Allahabad Bank
Cluster: Cannonball
Recommendation: Buy
Price target: Rs300
Current market price: Rs252

Upgraded to Buy

Result highlights

  • Q2 bottom line higher than expected: Allahabad Bank?s Q2FY2011 performance was better than our expectations. The bank?s net profit grew by 20.7% year on year (YoY) to Rs402.6 crore against our expectation of Rs385.7 crore. The profit growth was mainly driven by a strong growth in the net interest income (NII) and a robust growth in the advances during the quarter.
  • NIM expands QoQ: The NII for the quarter grew by a healthy 60.7% YoY to Rs969.2 crore. The NII growth was driven by an improved credit growth. Meanwhile the reported net interest margin (NIM) increased by 24 basis points sequentially. The sequential growth in the NIM was based on a 52-basis-point sequential increase in the yield on advances. 
  • Robust business growth: The bank?s advances grew by a robust 38.9% YoY to Rs83,183 crore as against deposits, which grew at a relatively slower rate of 30.2% to reach Rs113,633 crore. This led to an increase in the credit-deposit ratio from 69.9% in September 2009 to 73.2% in September 2010.
  • Healthy fee income: As expected, the performance on the non-interest income front was weak as the non-interest income declined by 14.8% YoY to Rs344.7 crore during the quarter. The non-interest income declined due to a 77.4% year-on-year (Y-o-Y) decline in the treasury income during the quarter. However, the fee income registered a strong growth of 17.0% YoY. 
  • Higher cost-income ratio: The growth in the operating expenses was higher at 48.6% YoY. Consequently, the cost-to-income ratio for the quarter stood at 40.5%, higher than the previous year?s figure. 
  • Depleted asset quality: The asset quality of the bank weakened on a sequential basis. The gross non-performing assets (GNPA) increased by 29.1% quarter on quarter (QoQ) to Rs1,470.3 crore and the net non-performing assets (NNPA) increased by 48% QoQ. In relative terms, the %GNPA increased to 1.77% from 1.50% in Q1FY2011. At the end of Q2FY2011 the restructured assets formed 3.6% of the advances book. The provisioning coverage ratio was at 81.02% at the end of the quarter.
  • CAR @ 13.49%: The capital adequacy ratio (CAR) of the bank as at the end of Q2FY2011 stood comfortable at 13.49%, though the same was lower than the CAR of 13.62% recorded during the previous quarter. The tier-1 CAR was at 8.41% at the end of Q2FY2011. 
  • Outlook: At the current market price of Rs252, the stock trades at 5.8x its FY2012E earnings per share (EPS), 3x FY2012E pre-provisioning profit (PPP) per share and 1.4x FY2012E adjusted book value (ABV) per share. In view of the strong and higher than expected Q2FY2011 results, the bank?s current valuations appear reasonable. We have tweaked our earnings estimates for the bank in line with its results and upgraded our recommendation on the bank to Buy with a revised price target of Rs300.  

 

Click here to read report: Investor's Eye

 

 

Regards,
The Sharekhan Research Team

myaccount@sharekhan.com 

Manage your newsletter subscriptions